Evidence map›Paper›PMID 38740860›Full record

ReviewNature reviews. Rheumatology2024

Recent advancements in cartilage tissue engineering innovation and translation.

Rachel C Nordberg, Benjamin J Bielajew, Takumi Takahashi, Shuyan Dai, Jerry C Hu, Kyriacos A Athanasiou

Abstract readReview
In one paragraph

Review in Nature reviews. Rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Liquid-Responsive Shape-Memory Nanofiber-Reinforced Scaffolds for Cartilage Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. A Piezo-Mimetic Ionic Hydrogel Harnessing Joint Motion for Cartilage Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Cartilage-SpecificBiomedicines · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel C Nordberg *Department of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-6047-6009
Benjamin J Bielajew *Department of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.
Takumi TakahashiDepartment of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.
Shuyan DaiDepartment of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0009-0005-7341-4858
Jerry C HuDepartment of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0003-0651-1461
Kyriacos A AthanasiouDepartment of Biomedical Engineering, University of California Irvine, Irvine, CA, USA. athens@uci.edu.ORCID http://orcid.org/0000-0001-5387-8405

Funding

NRSA Training CoreTL1TR001415 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, HEAD, ELIZABETH · 2015 to 2023
$4.2M
Self-assembling process in tissue engineering of articular cartilageR01AR067821 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ATHANASIOU, KYRIACOS A · 2015 to 2019
$1.9M
Toward tissue engineering of facet cartilageR01AR078389 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ATHANASIOU, KYRIACOS A · 2021 to 2025
$1.7M
Tissue-engineered regeneration of the minipig TMJ condyleF32DE032896 · NIDCR · UNIVERSITY OF CALIFORNIA-IRVINE · PI BIELAJEW, BENJAMIN · 2023 to 2025
$224k
NCATS NIH HHS TL1 TR001415NIAMS NIH HHS R01 AR067821NIAMS NIH HHS R01 AR078389NIDCR NIH HHS F32 DE032896
6 · The paper itself

Abstract

Articular cartilage was expected to be one of the first successfully engineered tissues, but today, cartilage repair products are few and they exhibit considerable limitations. For example, of the cell-based products that are available globally, only one is marketed for non-knee indications, none are indicated for severe osteoarthritis or rheumatoid arthritis, and only one is approved for marketing in the USA. However, advances in cartilage tissue engineering might now finally lead to the development of new cartilage repair products. To understand the potential in this field, it helps to consider the current landscape of tissue-engineered products for articular cartilage repair and particularly cell-based therapies. Advances relating to cell sources, bioactive stimuli and scaffold or scaffold-free approaches should now contribute to progress in therapeutic development. Engineering for an inflammatory environment is required because of the need for implants to withstand immune challenge within joints affected by osteoarthritis or rheumatoid arthritis. Bringing additional cartilage repair products to the market will require an understanding of the translational vector for their commercialization. Advances thus far can facilitate the future translation of engineered cartilage products to benefit the millions of patients who suffer from cartilage injuries and arthritides.

Indexed as

Cartilage, ArticularTissue EngineeringAnimalsArthritis, RheumatoidHumansOsteoarthritisTissue ScaffoldsTranslational Research, Biomedical

Identifiers

PMID38740860
PMCPMC11524031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.